3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Thymus Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Neoplasms
1
Pancreatitis
1
Pancreatic Diseases
1
Neoplasms
1
Mesothelioma
1
Melanoma
1
Head and Neck Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Hepatocellular
1
Adenoma, Islet Cell
1
Adenocarcinoma
1
Interventions
Bevacizumab
47
lenvatinib
36
atezolizumab
36
durvalumab
28
tremelimumab
23
sintilimab
19
Nivolumab
18
pembrolizumab
14
Radiosurgery
13
tislelizumab
11
Specimen Handling
10
Ipilimumab
10
camrelizumab
8
apatinib
8
Oxaliplatin
8
Immune Checkpoint Inhibitors
8
Fluorouracil
8
Cyclophosphamide
8
Blood Specimen Collection
8
regorafenib
7
cabozantinib
7
fludarabine
6
Sorafenib
6
Radiotherapy
6
Magnetic Resonance Spectroscopy
6
Leucovorin
6
donafenib
5
Surgical Procedures, Operative
5
Injections
5
Immunoglobulin G
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Carcinoma, Hepatocellular
×
Histocompatibility Testing
×
Clear all
NCT07623265
2026-06-03
IO-MARC
Universitaire Ziekenhuizen KU Leuven
Phase NA
Recruiting
300 enrolled